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Available online 7 April 2016Genetic factors and hypoﬁbrinolytic statemay contribute to the likelihood of developing inmyocardial infarction
(MI) in young women rather than traditional risk factors. High plasminogen-activator inhibitor-1 (PAI-1) level
and PAI-1 gene polymorphism have been shown to be associated with thrombotic events such as myocardial
infarction, deep venous thrombosis, and stroke. We determined 4G/4G polymorphism in a 34-year-old female
patient with subacute anterior myocardial infarction and coronary thrombus in left anterior descending artery
on coronary angiogram.
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The pathogenesis of myocardial infarction (MI) is complex and
multifactorial, including multiple interacting environmental and
genetic factors. Traditional risk factors such as hypertension, diabetes
mellitus, and hypercholesterolemia are less pronounced in the younger
patients in development of the myocardial infarction. Therefore,
additional factors such as genetic factors and hypoﬁbrinolytic state
may contribute to the likelihood of developing in the myocardial
infarction and may be required to determine in young participants.1
Plasminogen-activator inhibitor-1 (PAI-1) is a member of serpin super-
family of protease inhibitors and a key regulatory protein of ﬁbrinolysis
cascade by inhibiting plasminogen activators which are tissue plasmin-
ogen activator (t-PA) and urokinase (u-PA).2 High plasma PAI-1 levels
have been shown to be associated with atherosclerosis, restenosis, and
in the pathogenesis of disorders associated with thrombotic events
such as myocardial infarction and deep venous thrombosis.2–4 It was
reported that PAI-1 gene polymorphism such as 4G/5G and 4G/4G
genotypes has been associated with the higher gene expression and
higher PAI-1 levels in the circulation resulting in an increased risk for
thrombotic events such as MI and stroke.5–10kalyoncuoglu80@gmail.com
.irfansahin@gmail.com
gmail.com (S. Özcan),
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A 34-year-old female patient had been admitted for chest pain of
about 5 days, which accelerates with exertion and resolves with rest.
She has no any history of smoking, alcohol, drug abuse, systemic
disease, or family history of cardiovascular disease. Blood pressure
was 115/70 mm Hg and heart rate was 88 BPM. Cardiac auscultation
was normal heart sounds with nomurmur. Other physical examination
ﬁndings were normal. ECG revealed loss of R progression on V2–3, ST
segment elevation on V2–5, and new developed deep inverted T
waves on V1–V6 (Fig. 1). Twoweeks before symptoms, ECGwas normal
with positive T waves. Echocardiography was normal with absence
of any wall motion abnormalities. Blood tests were troponin
0.419 mcg/L, CK-MB b21 ng/mL. Coronary angiogram revealed long
intracoronary thin thrombus adjusted to endothelium at LAD artery
(Fig. 2). Because of lack of response to repeated dosages of intracoronary
nitroglycerin, and typical thin trombus appearance, vasospastic angina
was excluded. Patient has received tiroﬁban infusion for 24 hours.
Repeat coronary angiogram has shown partial resolution of coronary
thrombus (Fig. 3). During hospital care, chest pain diminished with
enoxaparine 6000 IU twice daily, clopidogrel 75 mg, acetyl salicylic
acid 300 mg, metoprolol 50 mg, and nitrate therapy. Statin therapy
was not initiated because of absent conventional risk factors. ECG
follow-up showed that resolution of ST segment elevation, but negative
T waves were persisted. Warfarin was started and acetyl salicylic acid
dose was adjusted as 100 mg per day. Patient has been discharged
with prescribing same medical treatment. Genetic analysis showed
that negative for protrombin genemutation (G20210A), Factor V Leidenier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. ECG on admission.
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mutation, antithrombin III, antiphospholipid antibody.
Lupus anticoagulant had a weak positive result of 1.35, thought as
clinically irrelevant (cut-off value: negative: b1.2; weak positive: 1.2–
1.5, positive: N1.5, markedly positive: N2.0). Heterozygot MTHFR
(A1298C) mutation has been revealed as positive, but homosistein
levels were normal, and there was weak evidence of developing throm-
bus with this mutation in current literature. Protrombine Activator
Inhibitor 1 (PAI-1) serpine 4G/4Gmutation has been revealed by genetic
analysis. This mutation has been known to be a high risk for thrombotic
events. So we thought it was responsible for this event. During follow-
up, the patient has complained of intermittent chest pain with short
duration as couple of minutes and resolves spontaneously. After
2 months, ECG ﬁndings were similar with negative T waves on V1–V6,
and there was short duration of angina attacks. At 4 months, ECG
revealed that negative Twavewas only at V2–V3 leads, and at 5months,
ECG was normal with positive T waves and clinically asymptomatic.
Discussion
An increased capacity to form blood clots or decreased ﬁbrinolytic
capacity due to high plasma PAI-1 levels has been shown to play an im-
portant role in the pathogenesis of disorders associatedwith thrombotic
events such as MI and ischaemic stroke.1,8,11,12 It was also found thatFig. 2. Coronary thrombus on left anterior descending artery.increased levels of PAI-1 were associated with coronary endothelial
dysfunction, plaque progression, and vulnerability leading to unstable
angina pectoris and acute myocardial infarction.2,13–15 It has been also
reported that several genetic variations in coagulation and ﬁbrinolytic
proteins were associated with the development of the risk of MI.7 The
PAI-1 gene known as SERPIN 1 gene in humans is located on chromo-
some 7q22.4 Two genetic variations, which were guanosine insertion/
deletion, −675 4G/5G, and −844 G/A promoter polymorphisms
in the PAI-1 gene, have been associated with increased PAI-1 levels
and linked to various vascular diseases such as MI and deep vein
thrombosis.5,7,13,16,17 Homozygosity for the deletion genotype (4G/4G)
has been associated with higher gene expression than those associated
with the insertion genotype (5G/5G) resulting in higher PAI-1 levels in
the circulation and an increased risk for venous thrombosis, pulmonary
thromboembolism, and MI through impairment of ﬁbrinolytic function
by elevated PAI-1 activity.5,7,8,16,18 Plasma levels of PAI-1 have a wide
and peak in the morning, whereas concentrations of t-PA exhibit less
prominent circadian variation, and a relative hypoﬁbrinolytic state
may occur in themorningwith increased platelet reactivity. That condi-
tion may contribute to the increased risk of MI seen during this period.
In a study, it has been also reported that morning increase in PAI-1Fig. 3. After tiroﬁban infusion, thrombus with partial resolution persisted on the left
anterior descending artery.
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et al. showed that homozygosity for the PAI-1 4G allele was signiﬁcantly
associated with increased risk of myocardial infarction.7 In a large
Japanese study, the PAI 4G/5G polymorphisms appeared to be a risk
factor for myocardial infarction in women.19 In a recent study, Ismail
et al. found that PAI-1 genotype was higher in Egyptian patients with
myocardial infarction. There was about twofold increased risk of MI
associated with 4G4G+ 4G5G compared with 5G5G. However, in that
study, the PAI-1 polymorphism (4G) was not found associated with
MI, whereasmodest risk could not be excluded.13While thementioned
data suggested positive association between the development ofMI and
PAI-1 gene polymorphism, Atherosclerosis, Thrombosis, and Vascular
Biology Italian Study Group (2003), did not ﬁnd any association
between PAI-1 gene polymorphisms and the development of acute MI
at a young age (under the age of 45 years).20 Ding et al. also found
that PAI-1 gene polymorphisms were associated with high plasma
PAI-1 levels, whereas they were not associated with MI or stroke.21
There are some studies in the literature that reported that PAI-1
antigen levels are positively correlated with cholesterol, LDL-cholesterol,
VLDL, and triglyceride levels and negatively with HDL cholesterol.4,18,22
In addition, it was suggested that the 4G/4G genotype has been reported
to be associated with high cholesterol levels.22 It was also claimed that
the increase in PAI-1 levels resulting from the activation of the renin–
angiotensin system and hypertension in subjects with the 4G/4G
genotype.4 It was also found that smoking by patients carrying the 4G
allele may have an important impact on the frequency of MI.13 Conse-
quently, data about the relation of PAI-1 with myocardial infarction
are still inconclusive and contradictory.
The etiology of cardiovascular disease is multifactorial and strongly
involves genetic and environmental factors. The interaction of genetic
and traditional risk factors such as smoking, hypertension, hypercholes-
terolaemia may have a role in the development of MI. So that, identify-
ing them for primary prevention early in life, especially in the presence
of genetic predisposition, is important. Despite aforementioned data,
the clinical use of ﬁbrinolytic markers to determine coronary risk offers
onlymarginal value and nodata available suggest analysis ofﬁbrinolytic
function in addition to traditional risk scores. We propose that the
determination of well-described polymorphisms in the PAI-1 promoter
and other components of the ﬁbrinolytic system as a novel risk factor in
addition to traditional risk factors is important.
Conclusion
Certain genetic disorders have tendency to myocardial infarction.
Genetic testing should be considered for patients with young age,
atypical presentation, and who have speciﬁc angiographic ﬁndings.
Conﬂict of interest
No conﬂict of interest.
References
1. Siegerink B, Meltzer ME, de Groot PG, Algra A, Lisman T, Rosendaal FR. Clot lysis time
and the risk of myocardial infarction and ischaemic stroke in youn women: results
from the RATIO case-control study. Br J Haematol 2011;156:252–258.2. Figueras J, Monasterio J, Domingo E, Meneses B, Nieto E, Cortadellas J, Garcia-Dorado
D. Prothrombotic proﬁle in patients with vasospastic or non vasospastic angina and
nonsigniﬁcant coronary stenosis. Thromb J 2011;9:10.
3. De Young MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases
neointima formation in balloon-injured rat carotid arteries. Circulation 2001;104:
1972–1976.
4. Katrancioğlu, Nurkay, et al. PAI-1 4G/4G gene polymorphism is associated with
higher serum lipid level in Turkish population. Cumhuriyet Med J [S.l.] 2011 Sep.;33(3):
307–311http://dx.doi.org/10.7197/cmj.v33i3.1008000938 (ISSN 1305-0028 . Available
at: bhttp://dergi.cumhuriyet.edu.tr/cumucmj/article/view/1008000938N. Date
accessed: 30 Dec. 2015).
5. Assawamakin A, Sriratanaviriyakul N, Lalerd Y, et al. Meta-analysis of the plasmino-
gen activator inhibitor-1 (PAI-1) gene with insertion/deletion 4G/5G polymorphism
and its susceptibility to ischemic stroke in Thai population. Asian Biomed
04/2012;6(2):203–217 (Available at: b https://www.researchgate.net/publication/
224221857_Meta-analysis_of_the_plasminogen_activator_inhibitor-1_PAI-1_gene_
with_insertiondeletion_4G5G_polymorphism_and_its_susceptibility_to_ischemic_
stroke_in_Thai_populationN. Date accessed: 30 Dec. 2015. doi:).
6. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of
the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of
the tissue type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc
Dis 2001;11:294–299.
7. Boekholdt SM(SMB), Bijsterveld NR, Moons AHM, et al. Genetic variation in coagula-
tion and ﬁbrinolytic proteins and their relation with acute myocardial infarction.
Circulation 2001;104:3063–3068.
8. Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in
vessels of internal organs. Am J Hematol 2002;71:89–93.
9. Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-speciﬁc increase
in basal transcription of the plasminogenactivator inhibitor 1 gene is associated with
myocardial infarction. Proc Natl Acad Sci U S A 1995;14:1851–1855.
10. Spronk HMH, van der Voort D, ten Cate H. Blood coagulation and the risk of athero-
thrombosis: a complex relationship. Thromb J 2004;2:12.
11. Kohler HP, Grant PJ. Mechanisms of disease; plasminogen-activator inhibitor type 1
and coronary artery disease. New Engl J Med 2000;342:1792–1801.
12. Guimaraes Ana HC, Bruijne Emile LE, Lisman T, et al. Hypoﬁbrinolysis is a risk factor
for arterial thrombosis at young age. Br J Haematol 2009;145:115–120.
13. Ismail S, Abdel azeem AA, Abdel Hamid MA, Nowier SR, Morad H. The role of
4G/5G genetic polymorphism of plasminogen activator inhibitor-1 gene in
myocardial infarction among Egyptans. Life Sci J 2011;8(1):32–39 (Avaible at: https://
www.google.com.tr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=
0ahUKEwjum_e3gITKAhVI_SwKHWvrCv8QFggaMAA&url=http%3A%2F%2Fwww.
lifesciencesite.com%2Flsj%2Flife0801%2F06_4152life0801_32_39.pdf&usg=
AFQjCNFUJ3U-xrc7LSfz9zT0Xldw_BDyNw&bvm=bv.110151844,d.bGg&cad=rja).
14. De Young MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases
neointima formation in balloon-injured rat carotid arteries. Circulation 2001;104:
1972–1976.
15. Figueras J, Monasterio Y, Lidon RM, et al. Thrombin formation and ﬁbrinolytic activity
in patients with acute myocardial infarction or unstable angina. In-hospital course
and relationship with recurrent angina at rest. J Am Coll Cardiol 2000;36:2036–2043.
16. Oszajca K, Wronski K, Janiszewska G, Bienkiewicz M, Bartkowiak J, Szemraj J. The
study of t-PA, u-PA, and PAI-1 genes polymorphisms in patients with abdomimal
aortic aneurysm. Mol Biol Rep 2014;41:2859–2864.
17. Buchholz T, Lohse P, Rogenhofer N, et al. Polymorphisms in the ACE and PAI-1 genes
are associated with recurrent spontaneous miscarriages. Hum Reprod 2003;18(11):
2473–2477.
18. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction
from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916–1923.
19. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group (2003). No
evidence of association between prothrombotic gene polymorphisms and the
development of acute myocardial infarction at a young age. Circulation 2003;107:
1117–1122.
20. Ding J, Nicklas BJ, Fallin MD, et al. Plasminogen activator inhibitor type 1 gene
polymorphisms and haplotypes are associated with plasma plasminogen activator
inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J
2006;152(6):1109–1115.
21. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The
effect of the plasminogen activator inhibitor-1 4G/5G gene polymorphism on the
thrombotic risk. Thromb Res 2008;122:736–742.
22. Boncoraglio GB, Bodini A, Brambilla C, Carriero MR, Ciusani E, Parati EA. An effect of
the PAI-1 4G/5G polymorphism on cholesterol levels may explain conﬂicting associ-
ations with myocardial infarction and stroke. Cerebrovasc Dis 2006;22(2-3):191–195.
